PNC Financial Services Group Inc. grew its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 1.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,974 shares of the medical research company’s stock after buying an additional 242 shares during the period. PNC Financial Services Group Inc.’s holdings in Charles River Laboratories International were worth $2,324,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Charles River Laboratories International by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 5,033,513 shares of the medical research company’s stock worth $452,764,000 after buying an additional 225,563 shares during the last quarter. BlackRock Inc. raised its position in shares of Charles River Laboratories International by 4.6% during the 2nd quarter. BlackRock Inc. now owns 4,022,882 shares of the medical research company’s stock valued at $406,913,000 after buying an additional 177,239 shares in the last quarter. FMR LLC raised its position in shares of Charles River Laboratories International by 39.7% during the 1st quarter. FMR LLC now owns 2,488,113 shares of the medical research company’s stock valued at $223,806,000 after buying an additional 707,612 shares in the last quarter. State Street Corp raised its position in shares of Charles River Laboratories International by 1.1% during the 1st quarter. State Street Corp now owns 1,239,943 shares of the medical research company’s stock valued at $111,539,000 after buying an additional 13,759 shares in the last quarter. Finally, Van Berkom & Associates Inc. raised its position in shares of Charles River Laboratories International by 0.4% during the 2nd quarter. Van Berkom & Associates Inc. now owns 767,913 shares of the medical research company’s stock valued at $77,674,000 after buying an additional 2,970 shares in the last quarter. 95.37% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Charles River Laboratories International, Inc. (CRL) Shares Bought by PNC Financial Services Group Inc.” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/10/02/charles-river-laboratories-international-inc-crl-shares-bought-by-pnc-financial-services-group-inc.html.

Several research analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $110.00 target price for the company in a research report on Thursday, August 10th. BidaskClub raised Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 22nd. Jefferies Group LLC restated a “buy” rating on shares of Charles River Laboratories International in a research report on Wednesday, June 14th. Barclays PLC restated a “hold” rating and set a $102.00 price target on shares of Charles River Laboratories International in a research report on Wednesday, July 19th. Finally, Royal Bank Of Canada assumed coverage on Charles River Laboratories International in a research note on Tuesday, September 19th. They set a “sector perform” rating and a $110.00 price target for the company. Six investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. Charles River Laboratories International presently has a consensus rating of “Buy” and a consensus target price of $99.59.

In other news, insider Davide Molho sold 5,982 shares of the business’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $107.55, for a total value of $643,364.10. Following the sale, the insider now directly owns 22,714 shares in the company, valued at approximately $2,442,890.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider William D. Barbo sold 4,000 shares of the business’s stock in a transaction dated Thursday, August 17th. The stock was sold at an average price of $99.91, for a total transaction of $399,640.00. Following the completion of the sale, the insider now owns 20,424 shares in the company, valued at $2,040,561.84. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 25,880 shares of company stock worth $2,541,668. 2.20% of the stock is owned by insiders.

Shares of Charles River Laboratories International, Inc. (CRL) opened at 108.02 on Monday. The firm’s 50-day moving average is $103.50 and its 200 day moving average is $95.67. The stock has a market capitalization of $5.14 billion, a price-to-earnings ratio of 28.46 and a beta of 0.96. Charles River Laboratories International, Inc. has a 52-week low of $67.20 and a 52-week high of $109.59.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, August 9th. The medical research company reported $1.29 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.07. Charles River Laboratories International had a net margin of 10.13% and a return on equity of 27.02%. The company had revenue of $469.13 million for the quarter, compared to analysts’ expectations of $458.25 million. During the same quarter in the previous year, the business posted $1.20 earnings per share. Charles River Laboratories International’s quarterly revenue was up 8.1% on a year-over-year basis. Equities analysts expect that Charles River Laboratories International, Inc. will post $5.10 EPS for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Stock Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related stocks with our FREE daily email newsletter.